Summary of worldwide clinical trials of aztreonam in patients with lower respiratory tract infections.

Abstract

Aztreonam was administered to 226 patients with lower respiratory tract infections--primarily pneumonia (181 patients)--due to gram-negative bacilli. The clinical response rate was 93%, and the microbiologic cure rate was 78%. Most patients received 1-g or 2-g intravenous doses of aztreonam three times daily for at least five days. Ninety-eight of the 226 patients were involved in a randomized comparison of aztreonam with tobramycin; the latter drug was administered to a group of 34 patients. The overall microbiologic cure rates for the two drugs were 86% and 71%, respectively. Aztreonam is effective for the treatment of lower respiratory tract infections due to susceptible gram-negative bacilli.

• Authors: E A Swabb, C O Cone, J G Muir
• Journal: Reviews of infectious diseases (Rev Infect Dis) 1985 Nov-Dec Vol. 7 Suppl 4 Pg. S675-8 ISSN: 0162-0886 [Print] United States
• PMID: 3909323 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Aztreonam
• Tobramycin

Topics

• Aztreonam (therapeutic use)
• Bacterial Infections (drug therapy)
• Bronchitis (drug therapy)
• Clinical Trials as Topic
• Gram-Negative Bacteria
• Humans
• Pneumonia (drug therapy)
• Random Allocation
• Respiratory Tract Infections (drug therapy)
• Tobramycin (therapeutic use)